NOMADX Holdings LLC Launches to Commercialize its Rapid and Highly Sensitive Biological and Chemical Detection Platform and Portfolio of Automated Testing Applications
Chris Wilson, WCV partner and a 30-year senior partner of a multi-billion-dollar hedge fund, has been appointed Chairman of the NOMADX Board.
- Chris Wilson, WCV partner and a 30-year senior partner of a multi-billion-dollar hedge fund, has been appointed Chairman of the NOMADX Board.
- “NOMADX aims to commercialize a new generation of powerful detection systems that will enable anyone to perform accurate, rapid, and cost-effective environmental and biological testing.
- The cartridge and sample, after testing, can be retained for confirmatory testing, as the NOMADX protocol is non-destructive to the sample.
- The NOMADX platform pipeline will expand to include early detection in the field of oncology and rare diseases, as well as potential therapeutics for companion diagnostics.